Press Releases

Date Title and Summary Additional Formats
Toggle Summary Biocept Obtains Japanese Patent for its Target Selector Oncogene Mutation Enrichment and Detection Platform
Expands intellectual property to 30 issued patents globally for highly sensitive methods of detecting cancer biomarkers SAN DIEGO , Oct. 18, 2018 /PRNewswire/ -- Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically
View HTML
Toggle Summary Biocept to Present at The MicroCap Conference in New York on October 2
SAN DIEGO , Sept. 25, 2018 /PRNewswire/ --  Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that President and CEO Michael
View HTML
Toggle Summary Biocept Awarded Patent in Hong Kong for its Target Selector Platform Using Antibodies and a Microchannel to Perform Liquid Biopsy
Expands the Company's global patent estate for the capture and detection of rare cells of interest, including CTCs shed by solid tumors, in blood and other biofluids SAN DIEGO , Sept. 24, 2018 /PRNewswire/ -- Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests
View HTML
Toggle Summary Biocept Announces Pricing of $2.5 Million Registered Direct Offering Priced at Market
SAN DIEGO , Sept. 21, 2018 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC) (" Biocept " or the "Company"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, today announced it has
View HTML
Toggle Summary Biocept Names Edwin C. Hendrick as Senior Vice President, Chief Commercial Officer
SAN DIEGO , Sept. 10, 2018 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the appointment of Edwin C.
View HTML
Toggle Summary Biocept's Target Selector Platform Featured in Two Poster Presentations at the IASLC 19th World Conference on Lung Cancer
Clinical study data highlight the ability of Biocept's proprietary liquid biopsy technology to detect and monitor actionable biomarkers and circulating tumor cell counts in the blood and in cerebrospinal fluid of non-small cell lung cancer patients SAN DIEGO , Sept.
View HTML
Toggle Summary Highmark Health's VITAL Innovation Program testing benefits of Biocept's liquid biopsy platform for improving outcomes and lowering costs of treatment for patients with non-small cell lung cancer
Allegheny Health Network's Cancer Institute spearheading the evaluation PITTSBURGH and SAN DIEGO , Aug. 23, 2018 /PRNewswire/ -- Highmark Health announced today that through its VITAL Innovation Program, it is testing Biocept, Inc.'s Target Selector™ liquid biopsy platform designed to help
View HTML
Toggle Summary Biocept Reports Second Quarter 2018 Financial Results
Company to host conference call at 4:30 p.m. Eastern time today SAN DIEGO , Aug. 14, 2018 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer
View HTML
Toggle Summary Biocept to Release Second Quarter 2018 Financial Results and Host Investor Conference Call on August 14, 2018
SAN DIEGO , Aug. 9, 2018 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing proprietary liquid biopsy tests that provide clinically actionable information to physicians to improve cancer treatment, announces that it will release financial
View HTML
Toggle Summary Biocept Announces $11.6 Million in Expected Gross Proceeds from Recently Expired Rights Offering
SAN DIEGO , Aug. 9, 2018 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announced today that the Company's previously announced
View HTML